Clinical Trials
111 trialsNeoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
Shanghai Henlius Biotech
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
Fudan University
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
B2023-153
Sun Yat-sen University
Safety and Efficacy of NK510 to Treat Gastric Cancer
Base Therapeutics (Shanghai) Co., Ltd.
ROME
Fondazione per la Medicina Personalizzata
BiOnHER
Institut Català d'Oncologia
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
Zai Lab (Hong Kong), Ltd.
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HIST-RIC
Institut Paoli-Calmettes
Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC
The First Affiliated Hospital of Zhengzhou University
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Yantai Yuhuangding Hospital
VinCaT
National Cancer Institute, Naples
FB-12
NSABP Foundation Inc
Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
easy laugh
Shanghai Pudong Hospital
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
NeoPATH
Ruijin Hospital
Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)
Fudan University
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer
West China Hospital
HERES
Rigshospitalet, Denmark
A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer
Shengjing Hospital
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
First Affiliated Hospital Xi'an Jiaotong University
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Yonsei University
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
Sun Yat-sen University
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
Fudan University
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
ChineseAMS
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
ChineseAMS
Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer
Shanghai Zhongshan Hospital
Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status
NSABP Foundation Inc
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
Zhejiang Cancer Hospital
Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer
Fudan University
Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors
The University of Hong Kong-Shenzhen Hospital
HERMET
University of Kansas Medical Center
NeoTPPF
Fudan University
NSABP Biospecimen Discovery Project
NSABP Foundation Inc
Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
OmicsWay Corp.
Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib
ChineseAMS
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients
Peking University Third Hospital
Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors
Fudan University
Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab
Peking University Third Hospital
Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Pyramid
Tianjin Medical University Cancer Institute and Hospital